|
|
Vaccine Detail
|
rMV-S + rMV-N vaccine |
| Vaccine Information |
- Vaccine Name: rMV-S + rMV-N vaccine
- Target Pathogen: SARS-CoV
- Target Disease: Severe Acute Respiratory Syndrome (SARS)
- Type: Mixed vaccine of two viral vector vaccines
- Status: Research
- Host Species for Licensed Use: Mouse
- Antigen: codon-optimised spike glycoprotein (S), SARS-CoV nucleocapsid protein (N) (Liniger et al., 2008)
- Immunization Route: Intraperitoneal injection (i.p.)
- Description: Live attenuated recombinant measles viruses (rMV) expressing a codon-optimised spike glycoprotein (S) of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) (Weingartl et al., 2004).
|
| Host Response |
|
Mouse Response
- Host Strain: Ifnartm-CD46Ge transgenic mice(Liniger et al., 2008)
- Vaccination Protocol: Mice were immunized with 0.5 × 10^4 pfu of each recombinant virus per mouse (Liniger et al., 2008)
- Immune Response: Induction of both humoral neutralizing and cellular responses against SARS-CoV, and neutralizing immunity against MV. (Liniger et al., 2008)
|
| References |
Liniger et al., 2008: Liniger M, Zuniga A, Tamin A, Azzouz-Morin TN, Knuchel M, Marty RR, Wiegand M, Weibel S, Kelvin D, Rota PA, Naim HY. Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses. Vaccine. 2008; 26(17); 2164-2174. [PubMed: 18346823].
Weingartl et al., 2004: Weingartl H, Czub M, Czub S, Neufeld J, Marszal P, Gren J, Smith G, Jones S, Proulx R, Deschambault Y, Grudeski E, Andonov A, He R, Li Y, Copps J, Grolla A, Dick D, Berry J, Ganske S, Manning L, Cao J. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. Journal of virology. 2004; 78(22); 12672-12676. [PubMed: 15507655].
|
|
